1779 Stock Chart & Stats
$104.90
$6.10(6.17%)
―
--
Day’s Range― - ―
52-Week Range$72.65 - $165.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$7.23B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-1.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,059,220
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LongBio Pharma (Suzhou) Co., Ltd. Class H News
1779 FAQ
What was LongBio Pharma (Suzhou) Co., Ltd. Class H’s price range in the past 12 months?
LongBio Pharma (Suzhou) Co., Ltd. Class H lowest stock price was $72.65 and its highest was $165.90 in the past 12 months.
What is LongBio Pharma (Suzhou) Co., Ltd. Class H’s market cap?
LongBio Pharma (Suzhou) Co., Ltd. Class H’s market cap is HK$7.23B.
When is LongBio Pharma (Suzhou) Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LongBio Pharma (Suzhou) Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is LongBio Pharma (Suzhou) Co., Ltd. Class H overvalued?
According to Wall Street analysts LongBio Pharma (Suzhou) Co., Ltd. Class H’s price is currently Undervalued.
Does LongBio Pharma (Suzhou) Co., Ltd. Class H pay dividends?
LongBio Pharma (Suzhou) Co., Ltd. Class H does not currently pay dividends.
What is LongBio Pharma (Suzhou) Co., Ltd. Class H’s EPS estimate?
LongBio Pharma (Suzhou) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LongBio Pharma (Suzhou) Co., Ltd. Class H have?
LongBio Pharma (Suzhou) Co., Ltd. Class H has 75,059,220 shares outstanding.
What happened to LongBio Pharma (Suzhou) Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LongBio Pharma (Suzhou) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1779
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LongBio Pharma (Suzhou) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
59.94%
Trailing 12-Months
Company Description
LongBio Pharma (Suzhou) Co., Ltd. Class H
Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
―